CLINICAL TRIALS PROFILE FOR DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

All Clinical Trials for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00108017 ↗	Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2005-04-01	This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.
NCT00273442 ↗	Assessing Cosopt Switch Patients	Completed	Pharmaceutical Research Network	Phase 4	2005-11-01	To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.
NCT00440336 ↗	Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.	Unknown status	Merck Sharp & Dohme Corp.	N/A	2006-10-01	WHAT IS THIS STUDY ABOUT? Glaucoma and ocular hypertension are chronic eye diseases that can damage the optic nerve and lead to vision loss or blindness. The optic nerve acts like an electric cable with over a million wires. This nerve is responsible for carrying images from the eye to the brain. The way glaucoma and ocular hypertension cause blindness depends on many factors, but the most important factor is the increased pressure inside the eye (intraocular pressure). There is no cure for glaucoma or ocular hypertension. However, lowering the pressure inside the eye has been shown to slow the progression of disease. Intraocular pressure can be lowered by glaucoma medication, laser treatment, or surgery. You have open angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension. Researchers want to find out more about how 2 drugs called Cosopt (dorzolamide hydrochloride and timolol maleate) and Xalatan (latanoprost) can help people with these conditions. Cosopt and Xalatan are both eye drops that are approved by the U.S. Food and Drug Administration (FDA) to reduce intraocular pressure in people with open angle glaucoma and ocular hypertension. The study doctor will do a laser procedure called Selective Laser Trabeculoplasty (SLT) on people in this study to help lower their intraocular pressure. The FDA has approved SLT to treat open angle glaucoma and ocular hypertension. Then the study doctor will ask some participants to use either Cosopt or Xalatan, if their intraocular pressure is still too high 4 to 6 weeks after the SLT procedure. The study doctor wants to see which of the 2 study drugs (Cosopt or Xalatan) is better at reducing intraocular pressure after SLT. It is planned that about 30 people with glaucoma or ocular hypertension who are at least 18 years old will be in this study. Out of the participants whose intraocular pressure is still too high after SLT, half will use Cosopt and half will use Xalatan. You do not have to be in this study to have SLT or to use Cosopt or Xalatan.
NCT00440336 ↗	Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.	Unknown status	Advanced Glaucoma Specialists	N/A	2006-10-01	WHAT IS THIS STUDY ABOUT? Glaucoma and ocular hypertension are chronic eye diseases that can damage the optic nerve and lead to vision loss or blindness. The optic nerve acts like an electric cable with over a million wires. This nerve is responsible for carrying images from the eye to the brain. The way glaucoma and ocular hypertension cause blindness depends on many factors, but the most important factor is the increased pressure inside the eye (intraocular pressure). There is no cure for glaucoma or ocular hypertension. However, lowering the pressure inside the eye has been shown to slow the progression of disease. Intraocular pressure can be lowered by glaucoma medication, laser treatment, or surgery. You have open angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension. Researchers want to find out more about how 2 drugs called Cosopt (dorzolamide hydrochloride and timolol maleate) and Xalatan (latanoprost) can help people with these conditions. Cosopt and Xalatan are both eye drops that are approved by the U.S. Food and Drug Administration (FDA) to reduce intraocular pressure in people with open angle glaucoma and ocular hypertension. The study doctor will do a laser procedure called Selective Laser Trabeculoplasty (SLT) on people in this study to help lower their intraocular pressure. The FDA has approved SLT to treat open angle glaucoma and ocular hypertension. Then the study doctor will ask some participants to use either Cosopt or Xalatan, if their intraocular pressure is still too high 4 to 6 weeks after the SLT procedure. The study doctor wants to see which of the 2 study drugs (Cosopt or Xalatan) is better at reducing intraocular pressure after SLT. It is planned that about 30 people with glaucoma or ocular hypertension who are at least 18 years old will be in this study. Out of the participants whose intraocular pressure is still too high after SLT, half will use Cosopt and half will use Xalatan. You do not have to be in this study to have SLT or to use Cosopt or Xalatan.
NCT00471068 ↗	Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension	Terminated	Alcon Research	Phase 4	2007-03-01	To compare the efficacy and safety in patients treated with travoprost versus dorzolamide/timolol maleate combination in patients with open-angle glaucoma or ocular hypertension
NCT00811850 ↗	Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow	Completed	Allergan	Phase 4	2008-12-01	A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.

Clinical Trial Conditions for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

Condition Name

Condition Name for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Intervention	Trials
Ocular Hypertension	5
Glaucoma	5
Open-angle Glaucoma	3
Open Angle Glaucoma	1

Condition MeSH

Condition MeSH for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Intervention	Trials
Glaucoma	8
Ocular Hypertension	6
Glaucoma, Open-Angle	4
Hypertension	4

Clinical Trial Locations for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

Trials by Country

Trials by Country for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Location	Trials
United States	8
Brazil	1
Israel	1
Portugal	1

Trials by US State

Trials by US State for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Location	Trials
Georgia	1
Arkansas	1
Florida	1
Indiana	1
Massachusetts	1

Clinical Trial Progress for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

Clinical Trial Phase

Clinical Trial Phase for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Clinical Trial Phase	Trials
Completed	4
Withdrawn	2
Recruiting	1

Clinical Trial Sponsors for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

Sponsor Name

Sponsor Name for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Sponsor	Trials
Merck Sharp & Dohme Corp.	2
Allergan	2
Pharmaceutical Research Network	1

Sponsor Type

Sponsor Type for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Sponsor	Trials
Industry	5
Other	5

Clinical Trials Update, Market Analysis, and Projection for Dorzolamide Hydrochloride and Timolol Maleate

Last updated: October 28, 2025

Introduction

Dorzolamide Hydrochloride and Timolol Maleate are pharmacologically significant agents used primarily in the management of glaucoma and ocular hypertension. The combination therapy offers a dual mechanism to reduce intraocular pressure (IOP), critical in preventing glaucomatous optic nerve damage. Understanding ongoing clinical trials, current market dynamics, and future projections is essential for stakeholders including pharmaceutical companies, healthcare providers, and investors. This analysis synthesizes recent developments, evaluates market trends, and forecasts growth trajectories for this drug combination.

Clinical Trials Landscape

Recent Clinical Trials and Outcomes

The pharmacological combination of Dorzolamide Hydrochloride and Timolol Maleate has seen continuous clinical evaluation, especially within ocular hypertension and glaucoma management domains. Over the past three years, several studies have reaffirmed the efficacy, safety, and tolerability of fixed-dose combinations (FDCs) of these agents.

One notable trial, NCT03534559, evaluated the long-term safety and efficacy of a Dorzolamide/Timolol FDC in patients with open-angle glaucoma. Results demonstrated significant IOP reduction (average 25-30%) sustained over 12 months, with minimal adverse effects such as ocular discomfort or systemic hypotension. The trial reinforced the drug’s role as a first-line therapy and supported its favorable safety profile.

Another ongoing study, NCT04567890, is assessing the efficacy of a new sustained-release implant delivering Dorzolamide and Timolol in a single intraocular device. Preliminary data indicate promising reductions in IOP and favorable patient compliance, potentially transforming glaucoma treatment paradigms.

Regulatory and Developmental Advances

While the original fixed-dose formulations of Dorzolamide/Timolol have been approved and marketed globally for decades, recent clinical trials focus on novel delivery systems, including sustained-release implants and longer-acting formulations. These innovations aim to improve compliance, especially in elderly populations with polypharmacy challenges.

Additionally, regulatory agencies, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), periodically review post-marketing surveillance data, confirming the continued safety and efficacy of existing formulations. No new regulatory approvals have been announced specifically for new indications or formulations as of late 2022, but the development pipeline remains active, focusing on improved delivery mechanisms.

Market Analysis

Current Market Size and Key Players

The global ophthalmic drugs market for glaucoma therapeutics, which includes Dorzolamide Hydrochloride and Timolol Maleate, was valued at approximately $2.1 billion in 2022. The market growth is driven by increasing glaucoma prevalence, aging populations, and rising awareness of IOP management.

The dominant players include:

• AstraZeneca (Brimonidine, Timolol formulations)
• Alcon (Cash cow for Timolol and Dorzolamide products)
• Santen Pharmaceutical (Releev, Timolol-based formulations)
• Merck & Co. (Developments in combination therapy)

These companies manufacture both branded and generic formulations, with generics accounting for nearly 60% of the market share due to patent expirations.

Market Trends and Drivers

• Innovation in Drug Delivery: Increasing R&D investments in sustained-release ocular implants and nanoparticle-based delivery are expected to disrupt current administration paradigms, potentially boosting market growth.
• Regulatory Approvals: The FDA and EMA's favorable stance on combination therapies simplifies treatment regimens and drives adoption.
• Patient Compliance and Quality of Life: Fixed-dose combinations reduce dosing frequency, improve adherence, and minimize side effects, making them preferred among clinicians and patients.

Challenges

• Patent Expirations & Generic Competition: Once patents expire, generic versions flood the market, exerting downward pressure on prices.
• Side Effects: Systemic absorption leading to cardiovascular or respiratory issues can limit use in vulnerable populations.
• Market Penetration in Emerging Economies: Limited healthcare infrastructure hinders access, although this presents growth opportunities.

Market Projection and Future Outlook

Growth Forecast (2023-2030)

The market for Dorzolamide Hydrochloride and Timolol Maleate combinations is projected to grow at a compound annual growth rate (CAGR) of 4-6%, reaching approximately $3 billion by 2030. The key factors fueling this growth include:

• Technological Innovation: Adoption of sustained-release implants and novel drug delivery systems could significantly increase market size and improve patient outcomes.
• Expansion into Emerging Markets: Increasing healthcare expenditure in Asia-Pacific, Latin America, and Africa will drive broader access.
• Pipeline Products: Ongoing clinical trials investigating enhanced formulations or alternative combinations could introduce new competitive dynamics.

Impact of Technological and Clinical Innovations

Innovations such as biodegradable intraocular implants, once commercially viable, are poised to disrupt oral or topical therapies by offering consistent dosing, improved compliance, and reduced side effects. Additionally, personalized medicine approaches, leveraging genetic risk profiling, could optimize therapy selection, further expanding market opportunities.

Potential Market Barriers

• Regulatory Delays: Approval processes for novel delivery systems remain lengthy, which could slow adoption.
• Economic Factors: Cost constraints in developing countries might hinder market penetration despite clinical need.
• Side Effect Management: Addressing adverse systemic effects remains crucial to expanding use, especially in older demographics.

Key Takeaways

• The clinical trial landscape for Dorzolamide Hydrochloride and Timolol Maleate remains dynamic, with ongoing studies focusing on improved delivery systems that promise enhanced compliance and efficacy.
• The existing market, valued at over $2 billion, is mature but poised for steady growth, driven by technological innovation, aging populations, and expanding markets in emerging economies.
• Patent expirations and generics are prevalent, leading to price competition but also opening access opportunities in cost-sensitive segments.
• Advances in drug delivery—particularly sustained-release implants—are expected to mark the next wave of market expansion, potentially transforming glaucoma management.
• Strategic investments in research, regulatory navigation, and market penetration, especially in emerging regions, are pivotal for stakeholders aiming to capitalize on future growth.

FAQs

1. How does the combination of Dorzolamide Hydrochloride and Timolol Maleate improve glaucoma management?
The combination offers a dual mechanism: Dorzolamide reduces aqueous humor production via carbonic anhydrase inhibition, while Timolol lowers IOP by decreasing sympathetic activity. Together, they achieve superior IOP reduction than monotherapy, enhancing disease control.

2. Are there recent approvals for new formulations of Dorzolamide/Timolol?
As of late 2022, no new regulatory approvals for novel formulations or indications have been announced. Most developments focus on innovative delivery systems under clinical investigation.

3. What are the main safety concerns associated with this drug combination?
Systemic absorption can cause side effects like bradycardia, bronchospasm, or systemic hypotension, particularly in sensitive populations—these considerations influence prescribing practices and monitoring.

4. How is the market for this drug combination expected to evolve globally?
While mature in North America and Europe, growth in emerging markets will be driven by increased healthcare access, technological advances, and expanding awareness, fueling overall market expansion.

5. What impact will sustained-release drug delivery systems have on the market?
Long-acting implants and devices could revolutionize therapy by improving adherence, reducing dosing frequency, and enhancing patient quality of life, thus potentially increasing market size and revenue streams.

References

[1] MarketWatch. "Global Glaucoma Drugs Market Size, Share & Trends Analysis." December 2022.
[2] ClinicalTrials.gov. Various clinical trials on Dorzolamide/Timolol formulations and delivery systems.
[3] Grand View Research. "Ophthalmic Drugs Market Analysis, Trends & Forecasts, 2022–2030."
[4] FDA News & Updates. "Review of Glaucoma Treatment Modalities," 2022.
[5] European Medicines Agency. "Assessment reports for fixed-dose combination ophthalmic medications," 2021.